home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

252.86 -5.52 (-2.14%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Jazz Pharmaceuticals plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch ↗

May 18, 2024

President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA).

Via Benzinga

Topics Cannabis

3 Cheap Blue-Chip Stocks to Buy Now: May 2024 ↗

May 17, 2024

If stock market speculation isn't quite working in your favor, these cheap blue-chip stocks may be the boost your portfolio needs.

Via InvestorPlace

10 Health Care Stocks With Whale Alerts In Today's Session ↗

May 15, 2024

Via Benzinga

Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In ↗

May 14, 2024

Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028.

Via Benzinga

Topics Cannabis

Demystifying Jazz Pharmaceuticals: Insights From 15 Analyst Reviews ↗

May 02, 2024

Via Benzinga

Breaking Down Jazz Pharmaceuticals: 15 Analysts Share Their Views ↗

April 10, 2024

Via Benzinga

The Analyst Landscape: 12 Takes On Jazz Pharmaceuticals ↗

March 20, 2024

Via Benzinga

7 Cannabis Stocks to Buy for a Smoking-Hot 2024 ↗

May 09, 2024

Ignite your portfolio with these seven sizzling cannabis stocks. From industry leaders to innovative upstarts.

Via InvestorPlace

Topics Cannabis

The 7 Top-Selling Cannabis Companies Ranked by Revenue: Which Weed Stocks to Buy? ↗

May 08, 2024

These top cannabis stocks by revenue are among the world's best sellers, making them prime investment opportunities to capture legal changes.

Via InvestorPlace

Topics Cannabis

JAZZ Stock Earnings: Jazz Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024 ↗

May 01, 2024

JAZZ stock results show that Jazz Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

Via InvestorPlace

3 No-Brainer Stocks to Buy With $300 Right Now ↗

April 24, 2024

A modest amount of money can go a long way on Wall Street when it's put to work in time-tested businesses with well-defined catalysts.

Via The Motley Fool

How To Make Your Cannabis Business More Attractive For Investors In 2024: Advice On Financial Health & Innovation ↗

March 25, 2024

Via Benzinga

Topics Cannabis

Demystifying Jazz Pharmaceuticals: Insights From 4 Analyst Reviews ↗

February 29, 2024

Via Benzinga

Evaluating Jazz Pharmaceuticals: Insights From 7 Financial Analysts ↗

January 29, 2024

Via Benzinga

Decoding 6 Analyst Evaluations For Jazz Pharmaceuticals ↗

January 03, 2024

Via Benzinga

HC Wainwright & Co. Maintains Buy Rating for Jazz Pharmaceuticals: Here's What You Need To Know ↗

March 14, 2024

Via Benzinga

7 Biotech Stocks to Buy as Sector Rotation Ramps Up ↗

March 13, 2024

With digital innovation possibly getting overextended, now’s the time to consider biotech stocks for an incoming rotation.

Via InvestorPlace

Time Is Still The Enemy, Says Mom Who Moved Mountains For Her Epileptic Daughter & Still Advocates For Millions Of CBD Users ↗

March 12, 2024

Via Benzinga

7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff ↗

February 26, 2024

Although the health innovation space can be a risky environment, undervalued biotech stocks can take some of the edge off.

Via InvestorPlace

4 Exhilarating Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip ↗

February 24, 2024

The Nasdaq Composite is the only major stock index that hasn't put the 2022 bear market in the rearview mirror. For patient investors, it means bargains still abound.

Via The Motley Fool

Topics Stocks

3 Cannabis Stocks That Could Be Multibaggers in the Making: February Edition ↗

February 20, 2024

Don’t miss out, as the following cannabis stocks are severely undervalued and are set to increase sales and make huge profits in 2024.

Via InvestorPlace

Topics Cannabis

The Queen Of Marijuana Investing Used Psychology To Launch Her Successful Cannabis Investment Fund ↗

February 14, 2024

Via Benzinga

Topics Cannabis

3 Biotech Stocks to Buy on the Dip: February 2024 ↗

February 07, 2024

Here are three biotech stocks to buy that are trading at prices that may not account for potential breakthrough opportunities

Via InvestorPlace

3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List ↗

February 06, 2024

These biotech stocks offer investors huge potential in the future. Investors may want to consider these equities to enter the industry.

Via InvestorPlace

4 Eye-Catching Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip ↗

February 03, 2024

The growth-fueled Nasdaq Composite remains nearly 6% below its all-time high, which means amazing deals can still be found.

Via The Motley Fool

Topics Stocks

Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for January 2024 ↗

January 31, 2024

Biotech stocks are warming up in January and look to continue upward in 2024 as the economy improves. Here are three to check out.

Via InvestorPlace

Topics Economy

Japanese University Will Research Marijuana's Medical Uses In First-Of-Its-Kind Collaboration With Australian Company ↗

January 31, 2024

Via Benzinga

Topics Cannabis

2 Incredible Growth Stocks That Are Screaming Buys for 2024 ↗

January 22, 2024

These healthcare businesses are compelling buys for very different reasons.

Via The Motley Fool

4 Remarkable Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip ↗

January 13, 2024

The growth-fueled Nasdaq Composite remains 7% below its all-time high, which means bargains can still be found.

Via The Motley Fool

Topics Stocks

US Stocks Set To Open Weaker As Traders Eye Key Main Street Events: Analyst Sees Buying Opportunity On 'Stunning' Earnings Expectations ↗

January 03, 2024

Several market-moving catalysts, including the release of the Fed minutes, a Federal Reserve speech, and JOLTS data, could influence the day's market movement.

Via Benzinga

Topics Economy

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com